Biomarkers of colorectal cancer in individual therapy

doi:10.3760/cma.j.issn.1673422X.2015.09.019

Abstract

ZHANG Yi-Fan, YIN Hai-Tao . Biomarkers of colorectal cancer in individual therapy[J]. Journal of International Oncology, 2015, 42(8): 710-.

［1］ Duffy MJ. Predictive markers in breast and other cancers: a review［J］. Clin Chem, 2005, 51(3): 494503. ［2］ Voon PJ, Kong HL. Tumour genetics and genomics to personalise cancer treatment［J］. Ann Acad Med Singapore, 2011, 40(8): 362378. ［3］ Weberpals J, Garbuio K, O′Brien A, et al. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer［J］. Int J Cancer, 2009, 124(4): 806815 . ［4］ Yin M, Yan J, MartinezBalibrea E, et al. ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatinbased chemotherapies in gastric and colorectal cancer: a systemic review and metaanalysis［J］. Clin Cancer Res, 2011, 17(6): 16321640. ［5］ Edler D, Hallstrm M, Johnston PG, et al. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, diseasefree and overall survival in rectal cancer［J］. Clin Cancer Res, 2000, 6(4): 13781384. ［6］ Yamada H, Iinuma H, Watanabe T. Prognostic value of 5fluorouracil metabolic enzyme genes in Dukes′ stage B and C colorectal cancer patients treated with oral 5fluorourecilbased adjuvant chemotherapy［J］. Oncol Rep, 2008, 19(3): 729735. ［7］ Yamada T, Tanaka N, Yokoi K, et al. Correlation between clinical pathologic factors and activity of 5FUmetabolizing enzymes in colorectal cancer［J］. J Nippon Med Sch, 2008, 75(1): 2327. ［8］ Jeung HC, Rha SY, Shin SJ, et al. Predictive values of 5fluorouracil pathway genes for S1 treatment in patients with advanced gastric cancer［J］. Antieancer Drugs, 2011, 22(8): 801810. ［9］ Wiman KG. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient［J］. Oncogene, 2010, 29(30): 42454252. ［10］ Tang NP, Wu YM, Wang B, et al. Systematic review and metaanalysis of association between p53 codon 72 polymorphism and colorectal cancer［J］. Eur J Surg Oncol, 2010, 36(5): 431438. ［11］ Zaanan A, CuilliereDartigues P, Guilloux A, et al. Impact of p53 expression and microsatellite instability on stage Ⅲ colon cancer diseasefree survival in patients treated by 5fluorouracil and leucovorin with or without oxaliplatin［J］. Ann Oncol, 2010, 21(4): 772780. ［12］ Kim KH, Kwon HC, Oh SY, et al. Clinicopathologic signifcance of ERCC1, thymidylate synthase and glutathione Stransferase P1 expression for advanced gastric cancer patients receiving adjuvant 5FU and cisplatin chemotherapy［J］. Biomarkers, 2011, 16(1): 7482. ［13］ Subbarayan PR, Lee K, Ardalan B. Arsenic trioxide suppresses thymidylate synthase in 5FUresistant colorectal cancer cell line HT29 in vitro resensitizing cells to 5FU［J］. Anticancer Res, 2010, 30(4): 11571162. ［14］ Ozasa H, Oguri T, Uemura T, et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer［J］. Cancer Sci, 2010, 101(1): 161166. ［15］ Vignoli M, Nobili S, Napoli C, et al. Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5fluorouracil［J］. Pharmacol Res, 2011, 64(3): 242248. ［16］ Qiu LX, Tang QY, Bai JL, et al. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving ?uoropyrimidinebased chemotherapy: evidence from 24 studies［J］. Int J Cancer, 2008, 123(10): 23842389. ［17］ Stoehlmacher J, Park DJ, Zhang W, et al. Association between glutathione Stransferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer［J］. Natl Cancer Inst, 2002, 19, 94(12): 936942. ［18］ Tan KL, Jankova L, Chan C, et al. Clinicopathological correlates and prognostic significance of glutathione Stransferase Pi expression in 468 patients after potentially curative resection of node positive colonic Cancer［J］. Histopathology, 2011, 59(6): 10571070. ［19］ Arienti C, Tesei A, Verdecchia GM, et al. Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer［J］. Clin Colorectal Cancer, 2013, 12(2): 122127. ［20］ Etiennegrimaldi MC, Milano G, Maindraultgoebol F, et al. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response incolorectal cancer patients［J］. Br J Clin Pharmacol, 2010, 69(1): 5866. ［21］ CastilloFernández O, Santibáez M, Bauza A, et al. Methylenetetrahydrofolate reductase polymorphism (677 C>T) predicts long time to progression in metastatic colon cancer treated with 5fluorouracil and folinic acid［J］. Arch Med Res, 2010, 41(6): 430435. ［22］ Fujiwara Y, Minami H. An overview of the recent progress in irinotecan pharmacogenetics［J］. Pharmacogenomics, 2010, 11(3): 391406. ［23］ MartinezBalibrea E, Abed A, MartlnezCardas A, et al. UGT1 A1 and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with flintline irinotecan and flurouracil combination therapy［J］. Br J Cancer, 2010, 103(4): 581589.

Biomarkers of colorectal cancer in individual therapy

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments